Idactamab INT-001 represents the promising medicinal approach for treating certain blood-related tumors. This immunoglobulin is an distinct mechanism of action, particularly interacting with CD-38, a membrane molecule https://bookmarklinking.com/story10928713/idacta-mab-int-001-the-new-antibody-during-testing